Document Detail


Effect of high-dose etodolac on renal function.
MedLine Citation:
PMID:  2957139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Previous studies from our laboratory have demonstrated transient effects on renal function by etodolac, 200 mg b.i.d. The current study assessed the effects of a larger dose of etodolac (500 mg b.i.d.) to explore the time course of its renal effects and to determine whether the transient effect would become more prolonged with a larger dose. We studied 10 normal subjects and nine patients with renal insufficiency, examining the effects of the first 500 mg dose of etodolac as well as 4 days of b.i.d. administration. In both groups, etodolac transiently decreased fractional excretions of sodium and chloride and urinary prostaglandin E2. In patients, etodolac also transiently decreased inulin and para-aminohippuric acid clearances and urinary 6-keto-prostaglandin F1 alpha. Chronic administration caused no changes in renal function in either group. In summary, in this relatively small group of patients, high-dose etodolac caused only transient, fully reversible effects on renal function, the cumulative effect of which was negligible.
Authors:
D C Brater; D Brown-Cartwright; S A Anderson; M Uaamnuichai
Related Documents :
6694109 - Renal transport of netilmicin in the rat.
2527539 - Pharmacokinetics of cilazapril in patients with renal failure.
2458109 - Effects of arotinolol on hemodynamics and adrenergically induced renin release and rena...
2104499 - Effect of free radicals in ischaemic renal failure in the dog.
17635499 - The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist,...
543899 - Pharmacokinetics of azlocillin in children with cystic fibrosis.
16423479 - Analgesic and anticonvulsant effects of extracts from the leaves of kalanchoe crenata (...
3430729 - Systemic and coronary hemodynamic effects of beta-adrenoceptor blocking agents in coron...
8482649 - Effect of inhaled lyso-platelet-activating factor on airway microvascular leakage in th...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  42     ISSN:  0009-9236     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  1987 Sep 
Date Detail:
Created Date:  1987-10-22     Completed Date:  1987-10-22     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  283-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
6-Ketoprostaglandin F1 alpha / urine
Acetic Acids / pharmacology*
Adult
Aged
Aldosterone / blood
Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
Body Weight / drug effects
Dinoprostone
Etodolac
Humans
Kidney / drug effects,  physiology,  physiopathology*
Middle Aged
Potassium / blood
Prostaglandins E / urine
Reference Values
Renin / blood
Sodium / urine
Grant Support
ID/Acronym/Agency:
AM00705/AM/NIADDK NIH HHS; AM27059/AM/NIADDK NIH HHS; RR00633/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Acetic Acids; 0/Anti-Inflammatory Agents, Non-Steroidal; 0/Prostaglandins E; 363-24-6/Dinoprostone; 41340-25-4/Etodolac; 52-39-1/Aldosterone; 58962-34-8/6-Ketoprostaglandin F1 alpha; 7440-09-7/Potassium; 7440-23-5/Sodium; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevention of the complications of scoliosis by early detection.
Next Document:  Clinical pharmacology of trimetrexate.